vs
Side-by-side financial comparison of SHORE BANCSHARES INC (SHBI) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $59.1M, roughly 1.8× SHORE BANCSHARES INC). On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 11.8%). SHORE BANCSHARES INC produced more free cash flow last quarter ($59.2M vs $-34.8M).
Shore Bancshares Inc. is a U.S. regional bank holding company headquartered in Maryland. It offers a full range of retail and commercial banking services, including deposit products, personal and commercial loans, and wealth management solutions, primarily serving local individual customers, small businesses and mid-sized enterprises in its operating regions.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
SHBI vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $59.1M | $103.7M |
| Net Profit | — | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 35.2% | -31.7% |
| Net Margin | — | -29.4% |
| Revenue YoY | 11.8% | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | $0.48 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $59.1M | $103.7M | ||
| Q3 25 | $56.4M | — | ||
| Q2 25 | $56.6M | — | ||
| Q1 25 | $53.0M | — | ||
| Q4 24 | $52.9M | — | ||
| Q3 24 | $50.5M | — | ||
| Q2 24 | $50.6M | — | ||
| Q1 24 | $47.7M | — |
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $14.3M | — | ||
| Q2 25 | $15.5M | — | ||
| Q1 25 | $13.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $11.2M | — | ||
| Q2 24 | $11.2M | — | ||
| Q1 24 | $8.2M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 35.2% | -31.7% | ||
| Q3 25 | 33.7% | — | ||
| Q2 25 | 36.5% | — | ||
| Q1 25 | 34.4% | — | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.7% | — | ||
| Q1 24 | 22.2% | — |
| Q4 25 | — | -29.4% | ||
| Q3 25 | 25.5% | — | ||
| Q2 25 | 27.4% | — | ||
| Q1 25 | 26.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 22.1% | — | ||
| Q2 24 | 22.2% | — | ||
| Q1 24 | 17.2% | — |
| Q4 25 | $0.48 | $-0.50 | ||
| Q3 25 | $0.43 | — | ||
| Q2 25 | $0.46 | — | ||
| Q1 25 | $0.41 | — | ||
| Q4 24 | $0.39 | — | ||
| Q3 24 | $0.34 | — | ||
| Q2 24 | $0.34 | — | ||
| Q1 24 | $0.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $355.6M | $197.9M |
| Total DebtLower is stronger | $89.1M | — |
| Stockholders' EquityBook value | $589.9M | $456.1M |
| Total Assets | $6.3B | $638.1M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $355.6M | $197.9M | ||
| Q3 25 | $416.5M | — | ||
| Q2 25 | $185.0M | — | ||
| Q1 25 | $389.0M | — | ||
| Q4 24 | $459.9M | — | ||
| Q3 24 | $183.6M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $114.6M | — |
| Q4 25 | $89.1M | — | ||
| Q3 25 | $74.5M | — | ||
| Q2 25 | $74.2M | — | ||
| Q1 25 | $74.0M | — | ||
| Q4 24 | $73.7M | — | ||
| Q3 24 | $123.5M | — | ||
| Q2 24 | $122.8M | — | ||
| Q1 24 | $72.6M | — |
| Q4 25 | $589.9M | $456.1M | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $565.2M | — | ||
| Q1 25 | $552.5M | — | ||
| Q4 24 | $541.1M | — | ||
| Q3 24 | $533.3M | — | ||
| Q2 24 | $522.8M | — | ||
| Q1 24 | $515.2M | — |
| Q4 25 | $6.3B | $638.1M | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.0B | — | ||
| Q1 25 | $6.2B | — | ||
| Q4 24 | $6.2B | — | ||
| Q3 24 | $5.9B | — | ||
| Q2 24 | $5.9B | — | ||
| Q1 24 | $5.8B | — |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.23× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $62.4M | $-24.8M |
| Free Cash FlowOCF − Capex | $59.2M | $-34.8M |
| FCF MarginFCF / Revenue | 100.2% | -33.5% |
| Capex IntensityCapex / Revenue | 5.4% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $110.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $62.4M | $-24.8M | ||
| Q3 25 | $42.5M | — | ||
| Q2 25 | $-8.3M | — | ||
| Q1 25 | $19.8M | — | ||
| Q4 24 | $46.9M | — | ||
| Q3 24 | $9.1M | — | ||
| Q2 24 | $3.0M | — | ||
| Q1 24 | $2.4M | — |
| Q4 25 | $59.2M | $-34.8M | ||
| Q3 25 | $41.9M | — | ||
| Q2 25 | $-9.2M | — | ||
| Q1 25 | $18.8M | — | ||
| Q4 24 | $41.7M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $614.0K | — |
| Q4 25 | 100.2% | -33.5% | ||
| Q3 25 | 74.3% | — | ||
| Q2 25 | -16.3% | — | ||
| Q1 25 | 35.4% | — | ||
| Q4 24 | 78.8% | — | ||
| Q3 24 | 16.7% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 5.4% | 9.6% | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 9.9% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 3.1% | — | ||
| Q1 24 | 3.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | -0.54× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | 0.27× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SHBI
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
